Spots Global Cancer Trial Database for A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)
Official Title: A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of ICP-022 in Patients With Relapsed/Refractory Marginal Zone Lymphoma (MZL)
Study ID: NCT03797456
Conditions
Interventions
Study Description
Brief Summary: The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022. Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R MZL will be evaluated in approximately 110 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Anhui Provincial Hospital, Hefei, Anhui, China
Anhui Cancer Hospital, Hefei, Anhui, China
Chinese People's Liberation Army General Hospital Fifth Medical Center, Beijing, Beijing, China
Peking university People's Hospital, Beijing, Beijing, China
Beijing Cancer Hospital, Beijing, Beijing, China
Union Hospital Affiliated to Fujian Medical University, Fuzhou, Fujian, China
The Second Hospital of Lanzhou University, Lanzhou, Gansu, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Henan Provincial People's Hospital, Zhengzhou, Henan, China
Henan Cancer Hospital, Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Hunan Cancer Hospital, Changsha, Hunan, China
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Jiangxi Cancer Hospital, Nanchang, Jiangxi, China
First Hospital of Jilin University, Changchun, Jilin, China
Shandong Provincial Hospital, Jinan, Shandong, China
Qilu Hospital of Shandong University, Jinan, Shandong, China
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Tianjin Cancer Hospital, Tianjin, Tianjin, China
Zhejiang University Medical School affiliated to the first Hospital, Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Contact Details
Name: Jun Zhu, PhD
Affiliation: Peking University Cancer Hospital & Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
